Reverse Merger - Summary of Final Purchase Price (Detail) - OncoGenex Pharmaceuticals, Inc [Member] $ / shares in Units, $ in Thousands |
Aug. 01, 2017
USD ($)
$ / shares
shares
|
|---|---|
| Business Acquisition [Line Items] | |
| Shares of the combined company to be owned by OncoGenex equity holders | shares | 273,671 |
| Multiplied by the price per share of OncoGenex stock | $ / shares | $ 46.20 |
| Value of shares of the combined company owned by OncoGenex equity holders | $ 12,643 |
| Fair value of options and warrants assumed | 207 |
| Fair value of contingent value rights assumed | 200 |
| Total purchase price | $ 13,050 |
| X | ||||||||||
- Definition Business combination share owned by acquiree equity holders. No definition available.
|
| X | ||||||||||
- Definition Business combination value of share owned by acquiree equity holders. No definition available.
|
| X | ||||||||||
- Definition Fair value of contingent value rights assumed. No definition available.
|
| X | ||||||||||
- Definition Fair value of options and warrants assumed. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Details
|